CAL101 anti-S100A4 antibody program
phase 2Prevent further decline in lung function in adults with idiopathic pulmonary fibrosis and treat fibrotic or fibro-inflammatory diseases by inhibiting proinflammatory and profibrotic S100A4 signaling.
Humanized monoclonal antibody targeting S100A4; Phase 2 randomized placebo-controlled IV infusion study comparing change from baseline in forced vital capacity, following earlier first-in-human safety, tolerability and pharmacokinetic testing of AX-202.
Phase 2 study of CAL101 in patients with idiopathic pulmonary fibrosis published on ClinicalTrials.gov.
Phase 1 clinical study of CAL101 was reported as successfully completed. Preclinical and translational evidence showed anti-S100A4 antibody treatment reduced profibrotic signaling and attenuated experimental skin fibrosis; AX-202 reduced profibrotic gene and protein expression in systemic sclerosis fibroblasts.